Clinical Trials Arena on MSN7d
Innovent Biologics doses first subject in trial of ovarian cancer therapyInnovent Biologics has dosed the first subject in the Phase III HeriCare-Ovarian01 trial of IBI354 for treating PROC with ...
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...
AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025AVA6103 IND-enabling studies underway with a Phase 1 trial ...
An oral dose of zoliflodacin – vying to become the first in the new class of bacterial type II topoisomerase inhibitors – was found to be as effective as the standard regimen of injectable ...
MacroGenics, Inc.’s MGNX share price has dipped by 14.19%, which has investors questioning if this is right time to buy.
The company will deliver an oral presentation on ADRX-0405, its clinical-stage STEAP1 ADC, and a poster presentation on ADRX-0134, its preclinical Na ...
Novel trispecific T cell engager, ZW209, demonstrates potent preclinical efficacy against DLL3-expressing tumors and an encouraging safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback